Moderna's stock is reportedly soaring, with some outlets suggesting it has already doubled in value this year. The increase may be related to a key FDA win, although the specifics of this development are unclear. Some investors are considering whether to buy the stock, while others are expressing caution, citing concerns about the company's need to generate profits and its future growth prospects.